ArticlePloS one2019
Expanding the watch list for potential Ebola virus antibody escape mutations.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Article
- Article
- ΦX174 bacteriophage viability predicted by protein biophysical modeling.bioRxiv : the preprint server for biology · 2025Article
- Exploring the expanse between theoretical questions and experimental approaches in the modern study of evolvability.Journal of experimental zoology. Part B, Molecular and developmental evolution · 2023Article
- The effect of mutations on binding interactions between the SARS-CoV-2 receptor binding domain and neutralizing antibodies B38 and CB6.Scientific reports · 2022Article
- Defining the HIV Capsid Binding Site of Nucleoporin 153.mSphere · 2022Article
- Article
- EfgA is a conserved formaldehyde sensor that leads to bacterial growth arrest in response to elevated formaldehyde.PLoS biology · 2021Article
- Implementing and Assessing an Alchemical Method for Calculating Protein-Protein Binding Free Energy.Journal of chemical theory and computation · 2021Article
- Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2.Cytotherapy · 2021Review
- Biosensors for Point Mutation Detection.Frontiers in bioengineering and biotechnology · 2021Article
- High resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies.bioRxiv : the preprint server for biology · 2020Article
- Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Viral genomics in Ebola virus research.Nature reviews. Microbiology · 2020Review
- Rapid exploration of the epitope coverage produced by an Ebola survivor to guide the discovery of therapeutic antibody cocktails.Antibody therapeutics · 2020Article
- Experimental evolution for niche breadth in bacteriophage T4 highlights the importance of structural genes.MicrobiologyOpen · 2020Article
- Assessment of software methods for estimating protein-protein relative binding affinities.PloS one · 2020Article
- Predicting the viability of beta-lactamase: How folding and binding free energies correlate with beta-lactamase fitness.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The 2014 outbreak of Ebola virus disease (EVD) in Western Africa is the largest recorded filovirus disease outbreak and led to the death of over 11,000 people. The recent EVD outbreaks (since May 2018) in the Democratic Republic of the Congo has already claimed the lives of over 250 people. Tackling Ebola virus (EBOV) outbreaks remains a challenge. Over the years, significant efforts have been put into developing vaccines or antibody therapies which rely on an envelope glycoprotein (GP) of Zaire ebolavirus (strain Mayinga-76). Therefore, one key approach for combating EVD epidemics is to predict mutations that may diminish the effectiveness of the treatment. In a previous study we generated a watch list of potential antibody escape mutations of EBOV GP against the monoclonal antibody KZ52. Molecular modeling methods were applied to the three-dimensional experimental structure of EBOV GP bound to KZ52 to predict the effect of every possible single mutation in EBOV GP. The final watch list contained 34 mutations that were predicted to destabilize binding of KZ52 to EBOV GP but did not affect EBOV GP folding and its ability to form trimers. In this study, we expand our watch list by including three more monoclonal antibodies with distinct epitopes on GP, namely Antibody 100 (Ab100), Antibody 114 (Ab114) and 13F6-1-2. Our updated watch list contains 127 mutations, three of which have been seen in humans or are experimentally associated with reduced efficacy of antibody treatment. We believe mutations on this watch list require attention since they provide information about circumstances in which interventions could lose the effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.